FTXH ETF Analysis: Nasdaq Pharmaceuticals | NASDAQ
Health | NASDAQ, USA | Market Cap: 912m USD | 12M Return: 52.6% | US33738R8372 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.55M
Warnings
No concerns identified
Tailwinds
Seasonality
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is a non-diversified fund that invests at least 90% of its net assets in the securities comprising its underlying index. The index is designed to track U.S. pharmaceutical companies selected based on liquidity and ranking criteria. The ETF launched on September 20, 2016, and has a small-cap market capitalization of $912 million.
The pharmaceutical sector centers on the research, development, manufacturing, and commercialization of drugs and therapies, with business performance typically tied to patent protection, R&D pipelines, and regulatory approvals. Sector-specific ETFs such as FTXH provide concentrated exposure to these companies, distinguishing them from broader healthcare funds that may also include medical devices, biotechnology, or managed care providers.
- Medicare drug price negotiations pressure pharma profit margins
- FDA approval pipeline drives pharmaceutical revenue growth
- Patent expirations trigger generic competition and revenue erosion
As of August 07, 2026, the stock is trading at USD 39.15 with a total of 127,476 shares traded. Over the past week, the price has changed by -0.38%, over one month by +0.61%, over three months by +13.45% and over the past year by +52.61%.
Current recommended Stop Loss: 38.20 (which is 2.4% or 1.2 ATR below the current price).
Nasdaq Pharmaceuticals has no consensus analysts rating.